Inhibitor of HMG-CoA reductase; decreases cholesterol biosynthesis, in vitro
and in vivo
. Induces apoptosis, arrests cancer cells in G1 phase and downregulates cdk 2, 4, and 6, cyclin D1 and E1, p21 and p27. Inactive lactam prodrug of mevastatin hydroxy acid, naturally bioactivated in vivo
following oral administration.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice.
Amin-Hanjani et al.
Effects of compactin, mevalonate and low-density lipoprotein on 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and low-density lipoprotein-receptor activity in the human hepatoma cell line Hep G2.
Cohen et al.
HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2.
Wachtershauser et al.
The citations listed below are publications that use Tocris products. Selected citations for Mevastatin include:
Showing Results 1 - 1 of 1